EVMN Insider Trading Activity and SEC Form 4 Filings
EVMN insider trading summary
Over the past 12 months, insiders at Evommune, Inc. (EVMN) reported 7 open-market purchases worth $70.2M by 6 insiders and 7 sales worth $1.5M by 4 insiders on SEC Form 4. Net insider buying was $68.6M.
Latest EVMN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 8, 2026 | Kyle Carver | Chief Financial Officer | Buy | $13K (1,000 @ $13.26) |
| Jul 7, 2026 | Arthur S Kirsch | Insider | Buy | $133K (10,000 @ $13.30) |
| Jun 22, 2026 | Janice Suzann Drew | Chief of Dev. Operations | Sell | $453K (20,000 @ $22.63) |
| Jun 22, 2026 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Sell | $33K (1,488 @ $22.50) |
| Jun 22, 2026 | Luis C. Pena | President & CEO | Sell | $169K (7,438 @ $22.71) |
| Jun 2, 2026 | David E Cohen | Insider | Sell | $13K (600 @ $21.38) |
| Jun 2, 2026 | David E Cohen | Insider | Sell | $110K (5,456 @ $20.21) |
| Jun 1, 2026 | Luis C. Pena | President & CEO | Sell | $382K (16,787 @ $22.74) |
| Jun 1, 2026 | Jeegar Pravinkumar Patel | Chief Scientific Officer | Sell | $379K (16,687 @ $22.74) |
| Dec 19, 2025 | Robert Lorne Hopfner | Director | Buy | $17K (1,000 @ $17.35) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.